Wen Shihong, Li Xiang, Ling Yihong, Chen Shaoqian, Deng Qiwen, Yang Lu, Li Ying, Shen Jiantong, Qiu Yuxin, Zhan Yaqing, Lai Hanjin, Zhang Xuyu, Ke Zunfu, Huang Wenqi
Department of Anesthesiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
Department of Anesthesiology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
FASEB J. 2020 Mar;34(3):4384-4402. doi: 10.1096/fj.201900817R. Epub 2020 Jan 21.
Reperfusion of the ischemic intestine often leads to drive distant organ injury, especially injuries associated with hepatocellular dysfunction. The precise molecular mechanisms and effective multiple organ protection strategies remain to be developed. In the current study, significant remote liver dysfunction was found after 6 hours of reperfusion according to increased histopathological scores, serum lactate dehydrogenase (LDH), alanine aminotransferase (ALT)/aspartate aminotransferase (AST) levels, as well as enhanced bacterial translocation in a rat intestinal ischemia/reperfusion (I/R) injury model. Moreover, receptor-interacting protein kinase 1/3 (RIP1/3) and phosphorylated-MLKL expressions in tissue were greatly elevated, indicating that necroptosis occurred and resulted in acute remote liver function impairment. Inhibiting the necroptotic pathway attenuated HMGB1 cytoplasm translocation and tissue damage. Meanwhile, macrophage-depletion study demonstrated that Kupffer cells (KCs) are responsible for liver damage. Blocking HMGB1 partially restored the liver function via suppressed hepatocyte necroptosis, tissue inflammation, hepatic KCs, and circulating macrophages M1 polarization. What's more, HMGB1 neutralization further protects against intestinal I/R-associated liver damage in microbiota-depleted rats. Therefore, intestinal I/R is likely associated with acute liver damage due to hepatocyte necroptosis, and which could be ameliorated by Nec-1 administration and HMGB1 inhibition with the neutralizing antibody and inhibitor. Necroptosis inhibition and HMGB1 neutralization/inhibition, may emerge as effective pharmacological therapies to minimize intestinal I/R-induced acute remote organ dysfunction.
缺血肠管再灌注常导致远处器官损伤,尤其是与肝细胞功能障碍相关的损伤。确切的分子机制和有效的多器官保护策略仍有待开发。在本研究中,在大鼠肠缺血/再灌注(I/R)损伤模型中,再灌注6小时后,根据组织病理学评分增加、血清乳酸脱氢酶(LDH)、丙氨酸氨基转移酶(ALT)/天冬氨酸氨基转移酶(AST)水平升高以及细菌易位增强,发现有明显的远处肝功能障碍。此外,组织中受体相互作用蛋白激酶1/3(RIP1/3)和磷酸化混合谱系激酶结构域样蛋白(p-MLKL)表达大幅升高,表明发生了坏死性凋亡并导致急性远处肝功能损害。抑制坏死性凋亡途径可减轻高迁移率族蛋白B1(HMGB1)的细胞质转位和组织损伤。同时,巨噬细胞清除研究表明,库普弗细胞(KCs)是肝损伤的原因。阻断HMGB1可通过抑制肝细胞坏死性凋亡、组织炎症、肝KCs和循环巨噬细胞M1极化部分恢复肝功能。此外,HMGB1中和进一步保护无菌大鼠免受肠I/R相关的肝损伤。因此,肠I/R可能与肝细胞坏死性凋亡导致的急性肝损伤有关,而Nec-1给药以及用中和抗体和抑制剂抑制HMGB1可改善这种情况。抑制坏死性凋亡和中和/抑制HMGB1可能成为有效的药物治疗方法,以尽量减少肠I/R诱导的急性远处器官功能障碍。